- Home
- GWRE vs BIIB Comparison
GWRE vs BIIB Comparison
Compare GWRE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRE
- BIIB
- Stock Information
- Founded
- GWRE 2001
- BIIB 1978
- Country
- GWRE United States
- BIIB United States
- Employees
- GWRE N/A
- BIIB N/A
- Industry
- GWRE Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GWRE Technology
- BIIB Health Care
- Exchange
- GWRE Nasdaq
- BIIB Nasdaq
- Market Cap
- GWRE 20.6B
- BIIB 18.7B
- IPO Year
- GWRE 2012
- BIIB 1991
- Fundamental
- Price
- GWRE $219.66
- BIIB $159.15
- Analyst Decision
- GWRE Buy
- BIIB Buy
- Analyst Count
- GWRE 14
- BIIB 24
- Target Price
- GWRE $270.77
- BIIB $174.62
- AVG Volume (30 Days)
- GWRE 699.9K
- BIIB 1.6M
- Earning Date
- GWRE 12-04-2025
- BIIB 10-30-2025
- Dividend Yield
- GWRE N/A
- BIIB N/A
- EPS Growth
- GWRE N/A
- BIIB N/A
- EPS
- GWRE 0.81
- BIIB 10.97
- Revenue
- GWRE $1,202,459,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- GWRE $18.42
- BIIB $2.97
- Revenue Next Year
- GWRE $15.10
- BIIB N/A
- P/E Ratio
- GWRE $270.91
- BIIB $14.52
- Revenue Growth
- GWRE 22.64
- BIIB 4.77
- 52 Week Low
- GWRE $165.09
- BIIB $110.04
- 52 Week High
- GWRE $272.60
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- GWRE 34.10
- BIIB 66.32
- Support Level
- GWRE $213.25
- BIIB $151.83
- Resistance Level
- GWRE $219.87
- BIIB $157.79
- Average True Range (ATR)
- GWRE 6.26
- BIIB 4.88
- MACD
- GWRE -3.10
- BIIB 0.68
- Stochastic Oscillator
- GWRE 14.97
- BIIB 99.65
About GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.